Carl Cook

Carl Cook took over as CEO of his parents' medical device manufacturer, Cook Group, when his father Bill died in 2011.

The $2.5 billion (sales) company sold one of its subsidiaries Cook Pharmica to drug delivery technology company Catalent for $950 million in 2017.

Cook's parents started the business in their Bloomington, Indiana apartment in 1963.

Cook is the president of a life sciences division called Cook MyoSite, which is developing a cell therapy to treat urinary incontinence.